SAR-442970 by Sanofi for Hidradenitis Suppurativa: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SAR-442970 overview

SAR-442970 is under development for the treatment of moderate to severe hidradenitis suppurativa (HS). It is administered through subcutaneous route in the form of solution. The therapeutic candidate acts by targeting OX40L and tumor necrosis factor alpha (TNFa). 

Sanofi overview

Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi’s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi is headquartered in Paris, Ile-de-France, France.

For a complete picture of SAR-442970’s drug-specific PTSR and LoA scores, buy the report here.

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.